March 01, 2015 8:48 PM ET

Biotechnology

Company Overview of DiObex, Inc.

Company Overview

DiObex, Inc. went out of business. DiObex, Inc. operates as a biotechnology company in the United States. The company develops novel products for the treatment of metabolic disorders, including type-one and type-two diabetes, dyslipidemia, obesity, and diabetic nephropathy. Its products include DIO-901, a very low dose glucagon product that is developed for the reduction of nocturnal hypoglycemia in patients with type-one diabetes; and DIO-902, a cortisol synthesis inhibitor that is developed as a therapy for glucose and cholesterol control in patients with type-two diabetes. DiObex, Inc. was founded in 2003 and is based in San Francisco, California.

600 Townsend Street

Suite 271

San Francisco, CA 94103

United States

Founded in 2003

Phone:

415-551-0400

Fax:

415-551-4113

Key Executives for DiObex, Inc.

DiObex, Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Wellstat Biologics Corporation United States
Preventive Medical Technologies United States
Excaliard Pharmaceuticals, Inc. United States
Glycobia, Inc. United States
Symbollon Pharmaceuticals Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DiObex, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.